Advanced search
Publication Cover
Clinical Ophthalmology Volume 15, 2021 - Issue
Submit an article Journal homepage
221
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease

Nicole Quah Qin Xian1 Department of Stroke Medicine, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UKView further author information
,
Ahmed Alnahrawy2 Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UKView further author information
,
Rashmi Akshikar2 Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UKView further author information
&
Vickie Lee2 Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK;3 Department of Surgery & Cancer, General Surgery, Faculty of Medicine,Imperial College London, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2963-5742View further author information
ORCID Icon
Pages 1921-1932 | Published online: 10 May 2021

References

  • Perros P, Cromble A, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1995;42(1):45–50. doi:10.1111/j.1365-2265.1995.tb02597.x
  • Genere N, Stan M. Current and emerging treatment strategies for Graves’ orbitopathy. Drugs. 2019;79(2):109–124. doi:10.1007/s40265-018-1045-9
  • Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of graves’ orbitopathy. Thyroid. 2008;18(3):333–346. doi:10.1089/thy.2007.0315
  • Ponto K, Pitz S, Pfeiffer N, Hommel G, Weber M, Kahaly G. Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int. 2009. doi:10.3238/arztebl.2009.0283
  • Wiersinga WM. Graves’ orbitopathy: management of difficult cases. Indian J Endocrinol Metab. 2012;16(Suppl 2):S150–2. doi:10.4103/2230-8210.104026
  • Mourits M, Prummel M, Wiersinga W, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9–14. doi:10.1046/j.1365-2265.1997.2331047.x
  • Bahn R, Gorman C. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am. 1987;16(2):391–407. doi:10.1016/s0889-8529(18)30485-7
  • Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13(4):388–391. doi:10.3928/1081-597X-19970701-16
  • Lee V, Avari P, Williams B, Perros P, Dayan C. A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom. Eye. 2019;34(9):1662–1671. doi:10.1038/s41433-019-0664-z
  • Smith T, Kahaly G, Ezra D, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761. doi:10.1056/nejmoa1614949
  • Douglas R, Kahaly G, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341–352. doi:10.1056/nejmoa1910434
  • Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy. Clin Endocrinol (Oxf). 2016;86(2):247–255. doi:10.1111/cen.13170
  • Kahaly G, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287–298. doi:10.1016/s2213-8587(18)30020-2
  • Kelada M, Avari P, Farag S, et al. Association of other autoimmune diseases in thyroid eye disease. Front Endocrinol. 2021;12:116. doi:10.3389/fendo.2021.644200
  • Staatz C, Tett S. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58. doi:10.2165/00003088-200746010-00002
  • Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil. Drug Saf. 2001;24(9):645–663. doi:10.2165/00002018-200124090-00002
  • Riedl M, Kuhn A, Krämer I, Kolbe E, Kahaly G. Prospective, systematically recorded mycophenolate safety data in Graves’ orbitopathy. J Endocrinol Invest. 2016;39(6):687–694. doi:10.1007/s40618-016-0441-9
  • Aktaran Ş, Akarsu E, Erbağci İ, Araz M, Okumuş S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2006;61(1):45–51. doi:10.1111/j.1742-1241.2006.01004.x
  • Marcocci C. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: Results of a Prospective, Single-Blind, Randomized Study. J Clin Endocrinol Metab. 2001;86(8):3562–3567. doi:10.1210/jc.86.8.3562
  • Feeney C, Lingam R, Lee V, Rahman F, Nagendran S. Non-EPI-DWI for detection, disease monitoring, and clinical decision-making in thyroid eye disease. Am J Neuroradiol. 2020;41(8):1466–1472. doi:10.3174/ajnr.a6664
  • Terwee C, Gerding M, Dekker F, Prummel M, Wiersinga W. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82(7):773–779. doi:10.1136/bjo.82.7.773

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.